Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 12, 1999

View Archived Issues

Micrologix initiates phase II safety studies of fast-track development candidate

Animal model shows Toleragen reduces production of antiphospholipid antibodies

Full enrollment reached in phase III trial of GMK cancer vaccine

MS-377 improves positive and negative symptoms of schizophrenia, without causing EPS

Cerus awarded NIH grant for allogeneic bone marrow transplant research

RPR sublicenses hormone replacement products to Novartis

Experimental hepatitis B vaccine includes a novel adjuvant; efficacy in nonresponders

Enzo Biochem's HGTV43 achieves high levels of gene delivery to human cells

Titan receives NIH grant for support of Parkinson's disease therapy

Sheffield and Elan establish licensing agreement to develop respiratory products

Venlafaxine as a nonhormonal treatment for hot flashes associated with androgen deprivation

Licensing opportunity from NIH: novel integrin antagonists for treating inflammatory disease

NO-generating prodrugs available for licensing from NIH

EM-800 unexpectedly found to resemble raloxifene more closely than fulvestrant

FDA approves Prozac for treatment of geriatric depression

Gemin X discovers novel Bcl-2 inhibitor as anticancer agent

Several candidates in Fujisawa's pipeline progressing in phase II and III trials

New British Biotech esters inhibit tumor cell proliferation

Potent and selective alpha1-adrenoceptor ligands and their use presented by Lundbeck

Inhibitors of Src PTKs from BMS particularly useful for T-cell-mediated disorders

Selective beta3-adrenoceptor agonists in development at Merck

Decatromicins: novel antibiotics produced by Actinomadura

Initial results point to efficacy and safety of BCH-10652 in HIV-infected patients

Activity of new triazole antifungal BMS-207147 further characterized in vitro

Triangle presents promising data on Coactinon at ICAAC, but reports interaction with nelfinavir

Antiretroviral-naive patients respond similarly to lodenosine and lamivudine in combination regimens

Popular Stories

News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Chinese biotechs gain leverage as partners in dealmaking
BioWorld
China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
Bio Korea 2026 kicks off with spotlight on oligonucleotides
BioWorld
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
Roche identifies new TREM2 agonists
BioWorld Science
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have prepared and tested new compounds acting as triggering receptor expressed on myeloid cells 2 (TREM2)...
Plasticity, properly parsed, provides psychiatric platform
BioWorld
If Benjamin Braddock, of The Graduate fame, were a young neuroscientist in the 21st century instead of a liberal arts graduate in 1967, the advice he received...